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Development/Plasticity/Repair

SRF Phosphorylation by Glycogen Synthase Kinase-3
Promotes Axon Growth in Hippocampal Neurons
Cong L. Li,1 Aruna Sathyamurthy,2 Anna Oldenborg,1 Dharmesh Tank,1 and Narendrakumar Ramanan1
1Department of Anatomy and Neurobiology and 2Department of Medicine, Division of Endocrinology, Washington University School of Medicine, St.
Louis, Missouri 63110

The growth of axons is an intricately regulated process involving intracellular signaling cascades and gene transcription. We had previously shown that the stimulus-dependent transcription factor, serum response factor (SRF), plays a critical role in regulating axon growth
in the mammalian brain. However, the molecular mechanisms underlying SRF-dependent axon growth remains unknown. Here we
report that SRF is phosphorylated and activated by GSK-3 to promote axon outgrowth in mouse hippocampal neurons. GSK-3 binds to
and directly phosphorylates SRF on a highly conserved serine residue. This serine phosphorylation is necessary for SRF activity and for
its interaction with MKL-family cofactors, MKL1 and MKL2, but not with TCF-family cofactor, ELK-1. Axonal growth deficits caused by
GSK-3 inhibition could be rescued by expression of a constitutively active SRF. The SRF target gene and actin-binding protein, vinculin,
is sufficient to overcome the axonal growth deficits of SRF-deficient and GSK-3-inhibited neurons. Furthermore, short hairpin RNAmediated knockdown of vinculin also attenuated axonal growth. Thus, our findings reveal a novel phosphorylation and activation of SRF
by GSK-3 that is critical for SRF-dependent axon growth in mammalian central neurons.
Key words: axon growth; filopodia; GSK-3; neurite outgrowth; serum response factor

Introduction
In developing CNS, neurite initiation and outgrowth are essential
to ensure proper development of axons and to establish functional neuronal connections (Zhou and Snider, 2006; Polleux
and Snider, 2010). SRF is a MADS-domain-containing transcription factor that is critical for expression of several stimulusactivated and cytoskeletal genes, including actin, vinculin, c-fos,
and egr-1 (Treisman, 1987; Miano, 2003; Ramanan et al., 2005).
Recent studies, including our own, using conditional knock-out
mice have shown that SRF plays a critical cell-autonomous role in
axonal growth both in vitro and in vivo (Knöll et al., 2006; Lu and
Ramanan, 2011). Despite these findings, the post-translational
mechanisms by which SRF activity is regulated in neurons as well
as the downstream target genes that are critical for mediating
axon growth remain poorly understood.
Among the intracellular signaling mechanisms, GSK-3 signaling has gained particular prominence in the regulation of both
neuronal polarity and axon outgrowth. GSK-3 is a serine/threonine kinase first characterized for its role in glycogen metabolism
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(Cohen and Frame, 2001; Doble and Woodgett, 2003). Recent
studies, using both pharmacological and genetic approaches to
block GSK-3 activity, have shown that GSK-3 is necessary for
axon growth (Kim et al., 2006; Garrido et al., 2007; Alabed et al.,
2010; Hur et al., 2011). Complete inactivation of GSK-3 kinases
resulted in strong inhibition of axon growth, which may be the
result of dampened microtubule dynamics (Kim et al., 2006; Alabed et al., 2010). A widely studied mechanism by which GSK-3
regulates axon growth is by regulating microtubule reorganization in the growth cone (Zhou et al., 2004; Yoshimura et al., 2005;
Kim et al., 2006). Despite these advances, whether GSK-3 activates transcriptional mechanisms critical for axon outgrowth remains known. It is possible that axonal growth deficits caused by
inhibition of GSK-3 activity could result, at least in part, from
inhibition of transcriptional programs critical for axon growth.
In this study, we identify SRF as a novel transcriptional target
of GSK-3 and show that phosphorylation of SRF by GSK-3 is
necessary for SRF transcriptional activity. Specifically, this phosphorylation is required for SRF interaction with the myocardin
family cofactors, MKL1 and MKL2, but not with the TCF-family
cofactor, ELK1. In addition, blockade of GSK-3 activity attenuates SRF target gene expression. Furthermore, SRF is sufficient to
promote axonal growth in the absence of GSK-3 signaling. We
also found that SRF is essential for filopodia formation, a necessary first step for Stage 1 axon growth. Finally, we demonstrate
that vinculin (VCL), an actin-binding protein and previously
identified SRF target gene, can promote axonal growth in SRFdeficient and GSK-3 inhibited neurons. Together, our findings
suggest that SRF is likely a critical transcription factor for GSK3-mediated axonal growth.
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Materials and Methods
Animals. The generation of Srf-f/f mice was previously described (Ramanan et al., 2005). These mice were bred to Nestin-Cre transgenic mice
(The Jackson Laboratory). Srf-NestinCKO mutant mice were obtained
from crosses between Srf-f/f and Srf-f/⫹;NestinCre double heterozygotes. Mice of either sex were used for preparing neuronal cultures. All
experiments were approved by Animals Studies Committee, Division of
Comparative Medicine, Washington University School of Medicine.
Immunohistochemistry. Immunohistochemistry was performed as
previously described (Ramanan et al., 2005; Lu and Ramanan, 2011).
Briefly, P0.5 animals were fixed by transcardial perfusion. The brains
were cryopreserved in 30% sucrose, frozen, and stored at ⫺80°C until
use. For staining, 12 to 16 m cryosections were made and incubated
in blocking/permeabilization solution containing 3% goat serum ⫹
0.3% Triton-X in PBS. The antibodies used are listed below (see
Immunocytochemistry).
Neuronal culture, transfection, and pharmacology. Hippocampus and
neocortex were dissected from postnatal 0.5 d (P0.5) mice, digested with
papain for 30 min at 30°C, and dissociated with micropipette tips in
culturing medium (Neurobasal-A medium supplemented with 0.5 mM
L-glutamine and B27 supplements, Invitrogen). Neurons were then
plated on coverglasses (Glaswarenfabrik Karl Hecht) coated with polyD-lysine or poly-D-lysine and laminin at a density of ⬃125 neurons/
mm 2. Neuronal cultures were incubated at 37°C with 5% CO2. After
neurons attached to poly-D-lysine coverglass (⬃15 min after plating), the
medium was gently exchanged to new neuronal culturing medium supplemented with 33 U/ml penicillin/streptomycin. After 4 d in culture,
neurons were fixed with 4% PFA/4% sucrose in PBS for 20 min. Neurons
were transfected using Amaxa Nucleofection (Lonza) according to the
manufacturer’s instructions. A total of 3–5 g of DNA was used for each
transfection. The inhibitors, 6-bromoindirubin-3⬘-acetoxime (500 nM,
Calbiochem) or lithium chloride (2 mM, Sigma-Aldrich) were directly
added to neuronal culture medium ⬃15 min after plating at the initial
medium exchange.
Phalloidin staining. Neuronal cultures were rinsed in PBS and fixed
in 1–2% paraformaldehyde in PBS for 15 min at room temperature;
0.1 M glycine was added to quench excess aldehyde for 5 min. The
cultures were then permeabilized with 0.1% Triton X-100 in PBS for
5 min and incubated in 1:125 dilution of rhodamine-phalloidin (Cytoskeleton) for 15 min. The cultures were washed with PBS for 5 min,
thrice, and mounted on slides.
Immunocytochemistry and quantification of axon growth. Neurons were
fixed at different time points. Fixed neurons on coverglass were blocked
and permeabilized with blocking solution (10% goat serum and 0.1%
Triton-X in PBS) for 30 min with gentle rocking, incubated with primary
antibody diluted in blocking solution for 45 min with gentle rocking,
washed with PBS for 2 min thrice, incubated with secondary antibody
diluted in blocking solution for 25 min with gentle rocking, and then
washed with PBS before mounting with vector shield mounting medium
supplemented with DAPI (Vector Laboratories). The following primary
antibodies were used: anti-SRF (1:2000, Santa Cruz Biotechnology),
anti-MAP2 (1:1000, Sigma), anti-␤-III tubulin (Tuj1, 1:1000, Sigma),
anti-Tau (1:1000, Millipore), anti-pan sodium channel, clone K58/35
(1:500, Sigma), anti-HA (1:1000, Sigma), and anti-Myc (1:100, Developmental Hybridoma). The secondary antibodies were AlexaFluor-488 and
-594 – conjugated anti-mouse or anti-rabbit at 1:1000 dilution (Invitrogen).
Only live neurons, based on the characteristic uncondensed DAPI staining,
were chosen for analysis in a double-blinded manner. Neurite growth was
analyzed by measuring the length of the longest neurite of Tuj1-positive
neurons. ImageJ software and NeuronJ plug-in were used to measure neurite
length, growth cone and cell soma areas, etc.
Immunoprecipitation. P0.5 mouse brains were dissected and homogenized in ice-cold protein extraction buffer: 20 mM HEPES, 125 mM NaCl,
5 mM MgCl2, 0.2 mM EDTA, pH 8, 1 mM EGTA, 1 mM NaF, 5 mM DTT,
glycerol, NP40, protease inhibitors (Roche), and phosphatase inhibitors
(Roche). The homogenate was centrifuged at 12,000 ⫻ g at 4°C for 10
min, precleared with beads, and supernatant was quantitated with Bradford reagent (Fermentas). A total of 10 l of protein-A magnetic beads

Li et al. • GSK-3–SRF Signaling Regulates Axon Growth

was washed with 0.1% BSA in PBS twice and 3 times with PBS. The
antibody of choice (1–3 g) was conjugated to the beads by incubating
with the beads on a rotary shaker for 1–3 h. The beads were then washed
3 times with PBS; 3 mg of total protein was mixed with the antibodyconjugated beads and incubated overnight at 4°C on the rotary shaker.
The following day, the magnetic beads were washed with protein extraction buffer 3 times. The beads were boiled with Laemmli sample buffer
before separation by SDS-PAGE electrophoresis. In addition to epitope
antibodies listed above, GSK-3␣/␤ antibody (Santa Cruz Biotechnology), GSK-3␤, and GSK-3␤ pSer9 antibody (Cell Signaling Technology)
were also used.
Site-directed mutagenesis. Site-specific mutants were generated using
QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to
the manufacturer’s instructions. Briefly, complementary primers of ⬃40
bp were designed with the mutation site in the middle of the sequence
and 25 ng of template DNA was used along with 25 pmol each of the
mutant primers. A 2 min extension for every 1 kb of template was used.
PCR for a total of 18 cycles was set as follows: 95°C for 3 min; 68°C for
(X-kb ⫻ 2 min); 18 cycles; 72°C for 10 min; end at 4°C. The reaction
mixture was digested with DpnI to remove template DNA and ligation
set with T4 DNA ligase for 1 h at room temperature. A small aliquot of the
reaction was transformed into DH10B, and transformants were selected
on appropriate antibiotic plates. The success of the site-directed mutation was confirmed by DNA sequencing of both strands of at least 2
independent clones.
Bacterial expression of proteins. SRF and SRF-S224A were cloned into
pGEX-4T-1 (GST tag vector) (BD Biosciences). BL21(DE3) strain of
Escherichia coli was transformed with the target constructs. Transformants were grown in LB medium until OD600 was ⬃0.6 and induced
with 1 mM IPTG at 16°C overnight. Bacteria were harvested the following
day, and GST-tagged target protein was purified using TALON affinity
cobalt column (Clontech) as per the manufacturer’s instructions. Purified proteins were quantitated, snap-frozen in liquid nitrogen, and stored
as single-use aliquots at ⫺80°C.
In vitro kinase assay. The different mutants of GSK-3␤ were expressed
and immunopurified from HEK293T cells as previously described (Cho
and Johnson, 2003). Briefly, HA-GSK-3␤-CA and HA-GSK-3␤-R96A
constructs were transfected into HEK293T cells by Amaxa Nucleofection
(Lonza). Immunoprecipitation assays were performed using anti-HA
antibody as described above with the following modification. In the final
step, beads were washed 3 times with 2⫻ kinase buffer (40 mM Tris, pH
7.4, 20 mM MgCl2, and 2.5 mM CaCl2) and resuspended in the 2⫻ kinase
buffer supplemented with 20 M ATP. The beads were incubated with the
same volume of bacterially purified GST-SRF, GST-SRF S224A, or GST
alone (1 g of protein used for SRF and S224A proteins and 0.373 g of
GST) along with 5 Ci of [␥- 32P]ATP. The samples were incubated at
37°C for 10 min, and the reaction was stopped by the addition of Laemmli buffer. The samples were then separated by SDS-PAGE gel, and the
radioactive signal was analyzed using a Phosphoimager.
In vivo kinase assay. HEK293T cells were cotransfected with HAtagged SRF or HA-SRF S224A along with Myc-GSK-3␤-WT, Myc-GSK3␤-KD, or Myc-GSK-3␤-CA. After 48 h, total lysate was prepared; SRF
was immunoprecipitated using anti-HA antibody and run on a 10%
SDS-PAGE gel. The Western blot was probed using a phospho-serine
antibody, anti-MPM2 (Invitrogen). The blot was then striped and
probed for total SRF.
Luciferase reporter gene assays. Luciferase assays were performed in
HEK293T. After transfection, cells were grown in serum-starved condition for 36 h; the medium was changed to that supplemented with 10%
FBS. Luciferase assay was performed using Dual Luciferase Assay kit
(Promega) 6 h after serum induction. Transfection efficiency was normalized using a second reporter gene, Renilla luciferase, and compared
with unstimulated controls.
Statistical analyses. Statistical differences were determined with one-way
ANOVA followed by Tukey’s post hoc test or with two-tailed Student’s t test
using GraphPad Prism software. Error bars in figures are SEM. “n” within
the bars denotes the number of cells counted for analysis.
Microarray analysis. Total RNA was isolated from the forebrain of P0.5
Srf-f/f and Srf-NestinCKO mice (n ⫽ 2) using PureLink RNA mini kit
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(Ambion). A total of 5 g of total RNA was submitted to the Multiplexed
Gene Analysis Core Facility, Washington University School of Medicine
(St. Louis, Missouri) for quality control, labeling, hybridization, scanning, and software services. Affymetrix Mouse Gene 1.0 ST was used for
the microarray, and data mining was performed using Partek Genomics
Suite software. Principal component analysis was performed to assess the
quality of the data. Genes that showed a fold change of at least 1.5 and a
present call in all 2 chips were considered. In addition, a two-tailed t test
with p ⬍ 0.05 was applied. From the list of downregulated genes, only
those that were either part of, or predicted to interact with, the cytoskeleton were used for further analysis. Figure 7 shows genes that were downregulated in Srf-NestinCKO mutant brains compared with control. After
validation using qRT-PCR, these genes were then screened for their ability to promote axon growth in SRF-deficient hippocampal neurons.
Image acquisition. Fluorescent and bright-field images were acquired
using Nikon 80i and Nikon 90i microscopes (Nikon Instruments), Roper
H2 cooled CCD camera (Photometrics), and Optigrid Structured Illumination Confocal with a Prior (Rockland) motorized translation stage.
Pseudo-colored images were acquired in MetaMorph (Molecular Devices), filtered, and levels were modified in ImageJ (National Institutes of
Health, Bethesda, Maryland) and Photoshop (Adobe) for clarity.

Results

GSK-3␤ phosphorylates SRF on a highly conserved
serine reside
SRF has been shown to regulate axonal growth in cultured hippocampal and DRG neurons (Knöll et al., 2006; Wickramasinghe
et al., 2008). Our recent findings using conditional SRF mutant
mice revealed that SRF is cell-autonomously required for growth
of several major axonal tracts, including corticostriatal and entorhinal– hippocampal axonal projections in vivo (Lu and Ramanan, 2011). To understand the molecular mechanisms by
which SRF regulates axonal growth, we first sought to determine
how SRF activity is regulated in neurons. Transcription factors, in
general, are regulated by at least two mechanisms: posttranslational modifications and association with specific cofactors. SRF has been shown to be phosphorylated upon synthesis,
but the regulation of its activity in neurons by phosphorylation
has not been reported (Misra et al., 1991; Rivera et al., 1993). We
took an in silico approach to identify phosphorylation sites on
SRF using Scansite (Obenauer et al., 2003). Among several residues identified as potential recognition motifs of different kinases, serine 224 (ser228 in human SRF) was predicted to be the
single target site for GSK-3␤. This serine residue lies within previously described GSK-3 consensus sequence, S/T-X-X-X-S/T, in
which the first Ser or Thr is the phosphorylated residue (Doble
and Woodgett, 2003) (Fig. 1A). Ser224 is highly conserved across
species, and structural analyses suggested that this residue should
be distant from target DNA binding and accessible for modification (Fig. 1 A, B) (Pellegrini et al., 1995). Interestingly, GSK-3inhibited wild-type and SRF-deficient neurons exhibit similar
morphologies, including highly attenuated axon growth, suggesting a possible functional link between SRF and GSK-3 (Goold et
al., 1999; Owen and Gordon-Weeks, 2003; Kim et al., 2006; Stern
et al., 2009; Hur et al., 2011).
Based on this prediction, we first examined whether SRF and
GSK-3 physically interact in the brain. Using pull-down assays
from wild-type brain lysates, we found that SRF and GSK-3 were
able to coimmunoprecipitate with each other (Fig. 1C). This was
further confirmed using Srf-NestinCKO and control brain lysates, in which GSK-3 coimmunoprecipitated with SRF from
control lysate alone but not from Srf-NestinCKO lysate (Fig. 1C).
Together, these experiments suggest that GSK-3 either directly
interacts with SRF or associates with the SRF transcriptional
complex.
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To address the functional relevance of the predicted phosphorylation and the coimmunoprecipitation results, we tested
whether GSK-3␤ directly phosphorylates SRF on ser224 residue
using in vitro kinase assay. Bacterially expressed and purified
GST, GST-SRF WT, or GST-SRF S224A was transiently incubated
with GSK-3␤-CA (constitutively active) or GSK-3␤-R96A (active
on unprimed substrates alone) or commercial GSK-3␤ kinase in
the presence of radioisotopic [␥- 32P]ATP (Cho and Johnson,
2003). SRF S224A was generated by mutating serine 224 to alanine
by site-directed mutagenesis. We found that SRF WT was efficiently phosphorylated by all three GSK-3 kinases (Fig. 1D). In
contrast, GST alone and SRF S224A mutant exhibited no phosphorylation signal in the presence of these GSK-3 kinases, suggesting that the phosphorylation occurs specifically on ser224
(Fig. 1D). GSK-3 has been shown to phosphorylate two classes of
substrates, primed and unprimed, depending on the requirement
of a priming phosphorylation on a discrete residue c-terminal to
the target site (Frame et al., 2001; Doble and Woodgett, 2003).
The unprimed status of a substrate can be determined using the
GSK-3␤-R96A mutant, which can bind to and phosphorylate
only unprimed substrates (Frame et al., 2001; Kim et al., 2006;
Twomey and McCarthy, 2006). The phosphorylation of bacterially generated SRF WT, which should lack any priming phosphorylation, by GSK-3␤-R96A suggests that SRF is an unprimed
substrate for GSK-3␤.
We next asked whether GSK-3 can also phosphorylate SRF in
vivo. This was studied using in vivo phosphorylation assays, in
which HEK293T cells were cotransfected with HA-SRF WT or
HA-SRF S224A along with GSK-3␤-WT, GSK-3␤-CA, or GSK-3␤KD. GSK-3␤-KD is a catalytically inactive mutant that functions
as a dominant-negative kinase and inhibits both GSK-3␣ and
GSK-3␤ (He et al., 1995; Kim et al., 2006; Kang et al., 2008). The
HA-SRFs were immunoprecipitated with anti-HA antibody and
phosphorylation was studied using a phospho-serine (pSer)specific antibody, anti-MPM2. We observed that SRF WT expressed alone exhibited a basal level of serine phosphorylation
and this is likely the result of phosphorylation on ser224 by endogenous GSK-3 or on serine residues by other kinases (Fig. 1E)
(Misra et al., 1991; Rivera et al., 1993). Expression of GSK-3␤-CA
or GSK-3␤-WT increased pSer levels, whereas GSK-3␤-KD expression attenuated pSer signal (Fig. 1 E, F ). Interestingly, the
pSer signal on SRF WT in the presence of GSK-3␤-KD expression
was lower than that seen when SRF WT alone was expressed, confirming the hypothesis that endogenous GSK-3 contributes to
basal serine phosphorylation on SRF (Fig. 1F, left; compare
SRF WT ⫹ Myc vs SRF WT ⫹ GSK-3␤-KD). In contrast, SRF S224A
point mutant exhibited neither any increase in phosphorylation in the presence of GSK-3␤-CA or GSK-3␤-WT nor any
attenuation of pSer phosphorylation when coexpressed with
GSK-3␤-KD (Fig. 1 E, F ).
Given that SRF is efficiently phosphorylated by GSK-3 both in
vitro and in 293T cells, we asked whether similar GSK-3mediated phosphorylation of SRF also occurs in neurons. We
inhibited GSK-3 kinases using the specific inhibitor, 6bromoindirubin-3⬘-acetoxamine (6-BIO) (500 nM) and then
probed for SRF phosphorylation with anti-pSer antibody. 6-BIO is
a cell-permeable small-molecule inhibitor that is highly selective for
GSK-3 but not for other kinases, including cyclin-dependent kinases
(Meijer et al., 2003; Kim et al., 2006). We found that SRF was robustly phosphorylated in cultured hippocampal neurons, and this
phosphorylation was significantly attenuated in the presence of
6-BIO (Fig. 1G,H). Together, these experiments demonstrate that
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Figure 1. SRF interacts with and is phosphorylated by GSK-3 on ser224. A, Protein alignment shows that ser224 in mouse SRF (ser228 in human) is highly conserved among different species. The
boxed region represents the suggested GSK-3 consensus sequence, S/T-x-x-x-S/T. B, Analysis of the solved x-ray crystal structure of the N-terminus 1–223 amino acids of human SRF bound to DNA
shows that the aspartate residue at 223 is far away from the DNA binding region of SRF. Therefore, the target serine 228 (human), located five amino acids further c terminus, is unlikely to interfere
with DNA binding. C, SRF and GSK-3 interact in the brain. SRF was immunoprecipitated from whole-brain lysate of P0.5 wild-type mice and immunoblotted for GSK-3 and SRF (top). GSK-3␣ and
GSK-3␤ were efficiently pulled down only with the SRF antibody and not with anti-IgG control antibody. Likewise, GSK-3 was able to pull down SRF only from wild-type but not from Srf-NestinCKO
brain lysate (bottom). Pull down using IgG alone served as control. D, SRF is efficiently phosphorylated by GSK-3␤ in vitro. Kinase assays ware performed using bacterially generated GST, GST-SRF,
or GST-SRF S224A along with either GSK-3␤-CA, GSK-3␤-R96A mutant kinases or commercial recombinant wild-type GSK-3␤ in the presence of [␥- 32P]ATP. GST-SRF alone was phosphorylated by
GSK-3␤-CA, GSK-3␤-R96A, and wild-type GSK-3␤. In contrast, SRF S224A mutant and GST alone showed no signal suggesting that there are no other GSK-3␤ sites on SRF. E, SRF is also
phosphorylated by GSK-3␤ in vivo. HEK293T cells were transfected with HA-tagged SRF WT or HA-SRF S224A along with empty Myc vector or with each of the different Myc-tagged GSK-3␤ kinases.
SRF was pulled down with anti-HA antibody and immunoblotted using anti-phosphoserine (anti-MPM2) and anti-SRF antibodies. The level of phosphorylation of HA-SRF WT increased in the
presence of active GSK-3␤ kinases (WT and CA), whereas phosphorylation is attenuated in the presence of GSK-3␤-KD mutant kinase. SRF S224A mutant did not exhibit any changes in phosphorylation levels. F, Densitometry analysis of results from E shows changes in phosphorylation levels relative to that for SRF WT or SRF S224A protein levels. Error bars indicate SEM. ***p ⬍ 0.001 (one-way
ANOVA, Tukey post-test analysis). n.s., Not significant. G, SRF is phosphorylated by GSK-3 in neurons. Hippocampal neurons from neonatal pups were grown (Figure legend continues.)
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SRF is a novel target of GSK-3 and is phosphorylated in an unprimed
manner on ser224 both in vitro and in cells.
Because GSK-3 phosphorylates SRF, we therefore examined
whether SRF phosphorylation is regulated in the brain during
development. SRF was immunoprecipitated from whole-brain
lysates at E13.5, E15.5, E18.5, P1, and P21, and status of serine
phosphorylation was probed using anti-pSer antibody (Fig. 1I ).
SRF expression increased during development and remained higher
postnatally (Fig. 1I). In contrast, SRF phosphorylation levels increased and peaked between E15.5 and E18.5. We then assessed for
GSK-3 activation by probing for GSK-3␤-Ser9 phosphorylation, a
measure of its inactivation (Cohen and Frame, 2001; Doble and
Woodgett, 2003). We observed that GSK-3␤-Ser9 phosphorylation
decreased between E15.5 and E18.5, suggesting that GSK-3␤ activity
increases during this time, similar to that observed for SRF-Ser224
phosphorylation (Fig. 1I,J). This increase in SRF phosphorylation
appears to coincide with active axonal growth that occurs after neurogenesis and is likely mediated by GSK-3.
Serine 224 phosphorylation by GSK-3 is critical for
SRF function
To assess whether ser224 phosphorylation is important for SRF
function, we asked whether SRF S224A mutant can rescue axonal
growth deficits of Srf-NestinCKO neurons. Reintroduction of
SRF WT into Srf-deficient neurons rescued axonal growth. In contrast, SRF S224A mutant was unable to rescue axonal growth in
Srf-NestinCKO neurons (Fig. 2 A, B). Interestingly, SRF S224A
acted as a dominant-negative mutant when expressed in wildtype neurons and attenuated axonal growth (Fig. 2C,D). We
compared this inhibitory effect of SRF S224A mutant on axonal
growth with two other dominant-negative SRF mutants, SRF-I
and SRF-En. SRF-I contains the N terminus homodimerization
and DNA binding domains alone but lacks the C terminus transactivation domain. SRF-I has been previously shown to be very
efficient in blocking activation of SRF-promoters in cultured cells
and is thought to function by either saturating SRF binding sites
on promoters or by sequestering endogenous SRF by forming
nonactive heterodimers (Kemp and Metcalfe, 2000). SRF-En is a
chimeric protein generated by fusing SRF-I with the repressor
domain (amino acids 2–298) of the engrailed gene from Drosophila (Jaynes and O’Farrell, 1991). Engrailed is a homeodomain
protein and is a potent repressor of transcription. This repressor
domain, when fused to other transcription factors, has been
shown to function as dominant-negative regulators of transcription (Badiani et al., 1994; Vickers and Sharrocks, 2002; Vickers et
al., 2004). Expression of SRF-I and SRF-En in wild-type neurons
4
(Figure legend continued.) for 3 d in the presence of either DMSO (vehicle) or 500 nM 6-BIO to
inhibit GSK-3. Endogenous SRF was immunoprecipitated with anti-SRF antibody and immunoblotted with anti-phosphoserine antibody. The level of serine phosphorylation decreased in the
presence of 6-BIO compared with DMSO-treated control. H, Densitometric analysis of phosphoSRF to total SRF levels from G shows significant decrease in SRF serine phosphorylation in the
presence of 6-BIO relative to DMSO control. Error bars indicate SEM. I, Changes in SRF and GSK-3
phosphorylation during brain development. SRF was immunoprecipitated from whole-brain
lysates of wild-type embryos and pups at the indicated stages and immunoblotted with pSer
antibody. GSK-3␤ activity was measured by immunoblotting for GSK-3␤-Ser9 phosphorylation. SRF expression increased during development, whereas the level of pSer phosphorylation
peaked⬃e15.5-e18.5.GSK-3␤-Ser9phosphorylationdecreasedbetweene15.5ande18.5andpostnatally,suggestingGSK-3␤ activationduringthistimeperiod.J,DensitometricanalysisofpSerlevels
and GSK-3␤-pSer9 from I shows increase in pSer phosphorylation of SRF and GSK-3␤ ⬃e15.5 to
e18.5.ErrorbarsindicateSEM.***p⬍0.001(one-wayANOVA,Tukeypost-testanalysis).**p⬍0.01
(one-way ANOVA, Tukey post-test analysis).
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also resulted in attenuated axonal growth similar to that of
SRF S224A mutant (Fig. 2C,D).
We next determined the effect of GSK-3 inhibition and SRFS228A mutation on SRF-dependent transcription. For this,
HEK293T cells were transfected with SRE-luciferase reporter
constructs and treated with either 6-BIO to inhibit GSK-3 activity
or cotransfected with SRF WT, SRF S224A, SRF-VP16, SRF-I, and
SRF-En (Fig. 2E). SRF-VP16 is a constitutively active chimeric
protein, which is generated by fusing 260 amino acids of SRF N
terminus with the strong transactivation domain of VP16 protein
from herpes simplex virus. SRF-VP16 transcriptional activity has
not been shown to depend on cofactor requirement or posttranslational modifications. Expression of SRF-VP16 results in
increased reporter activation, even in the absence of any inducing
stimulus (Fig. 2E). Inhibition of GSK-3 activity blocked seruminduced SRF-dependent transcription (Fig. 2E). Unlike SRF WT
but similar to SRF-I and SRF-En, SRF S224A mutant was also
incapable of activating SRF-dependent transcription (Fig. 2E).
Together, these experiments suggest that GSK-3 activity and SRFSer224 phosphorylation is critical for SRF function in neurons.
Phosphorylation of SRF by GSK-3 is necessary for MKL
cofactor binding
Given that Ser224 phosphorylation by GSK-3 is necessary for SRF
function, a critical question is how Ser224 phosphorylation contributes to SRF-dependent transcription. One of the widely described regulatory mechanisms for SRF-dependent transcription
is its association with specific cofactors (Sharrocks, 2001; Cen et
al., 2004). We therefore asked whether SRF S224A mutant can interact with TCF-family member ELK1 and myocardin-family
members MKL1 and MKL2 using coimmunoprecipitation assays. HEK293T cells were cotransfected with HA-tagged SRF WT
or SRF S224A along with Flag-MKL1 or Myc-MKL2. SRF was immunoprecipitated with anti-HA antibody and immunoblotted
for Flag or Myc epitopes. S224A mutation specifically attenuated
SRF binding to MKL1 and MKL2 (Fig. 3A,B). To probe ELK1 interaction, the ability of SRF WT and SRF S224A mutant to immunoprecipitate endogenous activated phospho-ELK1 (pELK1) was
analyzed. In contrast to MKL1 and MKL2, the interaction of
SRF S224A mutant with pELK1 was unaffected (Fig. 3C,D), suggesting
that phosphorylation of ser224 by GSK-3 is necessary for the recruitment of MKLs, but not TCF-family cofactors, onto SRF.
Previous studies have shown that the MKL-family cofactors
are required for axonal growth (Knöll et al., 2006; Wickramasinghe et al., 2008; Mokalled et al., 2010; O’Sullivan et al., 2010).
Consistent with these studies, we found that expression of a
dominant-negative MKL2 (DN-MKL2), which inhibits the activities of both MKL1 and MKL2, can block axonal growth in hippocampal neurons (Selvaraj and Prywes, 2003) (Fig. 3 E, F ). Thus
far, the requirement for TCF-family cofactors in regulating axon
growth has not been studied. Elk1-null mice are viable and do not
exhibit any structural abnormalities in the brain, and this is attributed to compensation by family members, Sap1 and Sap2
(Cesari et al., 2004). To address the requirement of TCF-family
cofactors for axon growth, we expressed ELK1-Engrailed (ELK1En), a chimeric protein generated by fusing ELK1 coding region
with the strong transcriptional repressor domain of the Drosophila gene, Engrailed. ELK1-En has been shown to efficiently inhibit
the activities of all three members of the TCF family (Vickers and
Sharrocks, 2002; Vickers et al., 2004). Expression of ELK1-En in
hippocampal neurons did not affect axon outgrowth (Fig. 3G,H ).
Together, these data suggest that phosphorylation of ser224 by
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Figure 2. Serine 224 is required for SRF function. A, SRF S224A mutant cannot rescue axonal growth deficits of SRF-deficient neurons. P0.5 hippocampal neurons from Srf-NestinCKO mice were
transfected with IRES-EGFP empty vector, HA-SRF WT, or HA-SRF S224A. Cells were fixed and immunostained for GFP or HA (green) to visualize transfected cells and anti-Tuj1 (red) at 4 DIV. Axonal
growth deficits exhibited by SRF-deficient neurons were rescued by SRF WT alone and not by empty vector or SRF S224A (arrows). Arrowhead indicates an untransfected cell. Scale bar, 50 m. B,
Quantitation of axon length from A. n ⫽ 4 mice; “n” in the bars indicates the number of cells measured for statistics. Error bars indicate SEM. ***p ⬍ 0.001 (one-way ANOVA, Tukey post-test
analysis). n.s., Not significant. C, SRF S224A functions as a dominant mutant when expressed in wild-type hippocampal neurons. Cells were transfected with HA-SRF WT or HA-SRF S224A and grown for
4 DIV. Cells were fixed and immunostained with anti-HA (green) and anti-Tau (red) antibodies. HA-SRF S224A expression attenuated axonal growth (arrows). Scale bar, 50 m. D, Data quantified
from C. Error bars indicate SEM. ***p ⬍ 0.001 (one-way ANOVA, Tukey post-test analysis). E, Inhibiting GSK-3 activity or mutating serine 224 to alanine abolishes SRF transcriptional activity.
HEK293T cells were transfected with 5⫻-SRE luciferase and Renilla luciferase (for transfection efficiency) and treated with either 6-BIO or cotransfected with control vector, SRF WT, SRF-S224A, or
SRF-VP16. 6-BIO treatment blocked serum-induced SRF-transcriptional activity. Whereas vector and SRF WT transfected cells showed normal activation of an SRE reporter, the SRF S224A mutant was
severely compromised in activating transcription. Expression of constitutively active SRF-VP16 served as the control. Error bars indicate mean ⫾ SEM.

GSK-3 and subsequent binding of MKLs and not TCF-family
members contribute to SRF-dependent axon growth.
SRF can rescue axon outgrowth deficits caused by
GSK-3 inhibition
Based on the above findings, we hypothesized that SRF likely functions downstream of GSK-3 signaling and that activation of SRFdependent gene expression should be able to promote axonal
growth when GSK-3 kinases are inhibited. To test this, SRFdependent gene expression was activated using constitutively active
SRF-VP16, whereas GSK-3 kinases were inhibited by LiCl (2 mM) or

6-BIO (500 nM) (Meijer et al., 2003; Kim et al., 2006). 6-BIO at 300
nM concentrations was found to be efficient in blocking GSK-3 activity and axon outgrowth in DRG neurons (Kim et al., 2006; Alabed
et al., 2010). However, we found that 500 nM of 6-BIO was more
efficient in blocking axonal growth in hippocampal neurons without
affecting neuronal survival (data not shown). Consistent with earlier
reports, culturing hippocampal neurons in the presence of LiCl or
6-BIO severely attenuated axonal growth (Kim et al., 2006; Alabed et
al., 2010) (Fig. 4A,B; and data not shown). SRF-VP16 expression in
neurons grown in the presence of 6-BIO or LiCl was able to significantly promote axon growth compared with IRES-EGFP control
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Figure 3. Serine 224 phosphorylation is required for SRF interaction with MKL-family cofactors and not with TCF-family cofactor ELK1. A, HEK293T cells were cotransfected with HA-SRF WT or HA-SRF S224A
along with Flag-MKL1 or Myc-MKL2. Immunoprecipitation with anti-HA antibody pulled down significantly less MKL1 (left) and MKL2 (right) from HA-SRF 224A-transfected cells. The expression levels of
Flag-MKL1,Myc-MKL2,andHA-SRFwerethesameinbothgroupsoftransfectedcells. ␤-TubulinlevelsinequalamountsoflysatesusedforIPservedasloadingcontrol.B,Densitometricanalysisofimmunoblot
in A. Error bars indicate SEM. C, Serine 224 to alanine mutation does not affect SRF interaction with the TCF-family member ELK1. HEK293T cells were transfected with HA-SRF WT or HA-SRF S224A. Immunoprecipitationwithanti-HAantibodyandimmunoblottingforendogenousactivatedELK1usinganti-phosphoELK1(pELK1)antibodyshowedthatasimilaramountofpELK1wasimmunoprecipitatedwithHA-SRF WT
andHA-SRF S224A.LevelsofSRFintheimmunoprecipitatesweresimilarand ␤-tubulinlevelsinequalamountsoflysatesusedforIPservedasloadingcontrol.D,DensitometricanalysisofimmunoblotinC.Error
barsindicateSEM.n.s.,Notsignificant.E,MKL1andMKL2arerequiredforaxongrowth.Neonatalwild-typehippocampalneuronsweretransfectedwithIRES-EGFPvectororDN-MKL2-IRES-EGFP.Expressionof
DN-MKL2 blocked axonal growth (arrow) as visualized with anti-Tau (red) and anti-GFP (green). Scale bar, 50 m. F, Quantitation of D. Error bars indicate SEM; n ⫽ 3 mice. ***p ⬍ 0.001 (two-tailed t test
analysis). G, Inhibition of TCF-family cofactors does not affect axonal growth. Hippocampal neurons from wild-type neonatal pups were transfected with dominant-negative Elk1-En (bottom) or empty vector
(top).CellswerestainedforTuj1(red)andFlagepitope(green)at4DIV.ExpressionofElk1-En,whichinhibitsallthreemembersoftheTCFfamily,doesnotaffectaxonalgrowth.Scalebar,50 m.H,Quantitation
of axon length in G. Error bars indicate SEM; n ⫽ 3 mice. p ⫽ 0.8087 (two-tailed t test analysis).
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Figure 4. SRF can rescue axonal growth deficits caused by GSK-3 inhibition. A, P0.5 hippocampal neurons from wild-type mice were transfected with either empty IRES-EGFP vector or
constitutively active SRF (SRF-VP16-IRES-EGFP) or constitutively active CREB (VP16-CREB) and grown in the presence of the GSK-3-specific inhibitor 6-BIO (500 nM) or DMSO (vehicle). Cells were fixed
and immunostained using anti-Tau (red) and GFP or VP16 (green) at 4 DIV. GSK-3 inhibition by 6-BIO results in attenuation of axonal growth (top, arrowhead), and this was rescued by expression
of SRF-VP16 (middle). Expression of a constitutively active CREB (VP16-CREB) was unable to promote axonal growth under similar growth conditions (bottom). Arrows indicate dead cells/debris.
Scale bar, 50 m. B, Quantitation of A. Error bars indicate SEM. **p ⬍ 0.01 (two-tailed t test analysis). ***p ⬍ 0.001 (two-tailed t test analysis). n.s., Not significant. C, Hippocampal neurons were
cotransfected with GSK-3␤ constructs and SRF-VP16 as indicated above and grown for 4 d. Expression of GSK-3␤-KD attenuated axon growth (middle). This attenuation was rescued by SRF-VP16
expression (bottom). Expression of GSK-3␤-WT alone had no influence on axon outgrowth. Arrows indicate dead cells/debris. Scale bar, 50 m. D, Axon length quantified from C. Error bars indicate
SEM. ***p ⬍ 0.0001 (one-way ANOVA, Tukey post-test analysis).

vector (Fig. 4A,B; and data not shown). Expression of SRF-VP16
alone in neurons did not produce any additional growth-promoting
effects under normal conditions (Fig. 4D). We next asked whether
this rescue specifically requires SRF or whether other transcription
factors can promote axonal growth under conditions of GSK-3 inhibition. Previous studies using knock-out mice have shown that
CREB is required for axonal growth in peripheral neurons (Lonze et
al., 2002; Gao et al., 2004). Expression of constitutively active CREB
(VP16-CREB) was unable to rescue the growth deficits resulting
from GSK-3 inhibition, indicating that CREB-dependent gene expression might be insufficient to rescue axonal growth when GSK-3
is inhibited (Fig. 4A,B). In addition to pharmacological inhibition,
we also expressed GSK-3␤-KD, which acts as a dominant-negative

mutant and has been shown to attenuate axon growth in cultured
hippocampal neurons (Fig. 4C) (Kim et al., 2006). Similar to that
seen for 6-BIO-mediated inhibition, expression of GSK-3␤-KD in
hippocampal attenuated axonal growth, and this was rescued by
SRF-VP16 expression (Fig. 4C,D). Together, these findings suggest
that SRF functions downstream of GSK-3 and that activation of
SRF-dependent expression can promote axon growth when GSK-3
activity is inhibited.
SRF is required during Stage 1 neurite growth and
axon extension
Given the importance of SRF for axon growth in vitro and in vivo,
it is critical to know when SRF-dependent transcription is re-
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Figure 5. SRF-deficient neurons are deficient in Stage 1 neurite growth and exhibit attenuated axonal growth in vitro. A, Hippocampal neurons from Srf-NestinCKO mice exhibit delayed and
attenuated axonal growth as visualized by immunostaining with Tuj1 (red) and MAP2 (green). SRF-deficient neurons produced fewer neurites at 12 h (arrows, left second row panels) and, at 5 d,
had shorter axons and enlarged growth cone (right bottom, arrow). Control neurons extended longer axon (right middle, arrow) and multiple dendrites. Arrowheads indicate dead cells. Scale bar,
50 m. B, Axonal growth in A was studied by measuring the length of the Tuj1 ⫹/MAP2 ⫺ process at the indicated time points. Error bars indicate SEM. C, Srf-NestinCKO neurons are deficient in
filopodia formation. Rhodamine-conjugated phalloidin reveals several filopodia (12 h, arrows) and distinct neurites (48 h) in control neurons. In contrast, mutant neurons had fewer or no filopodia
(arrow) and an enlarged cell body. Scale bar, 12.5 m. D, Histograms of the total filopodia counted from C. p ⬍ 0.0001 (two-tailed t test analysis). E, Immunostaining with axon-specific PanNaV
(green) and Tuj1 (red) antibodies shows normal polarization of Srf-NestinCKO neurons as observed for Srf-f/f neurons (n ⫽ 32). Scale bar, 25 m.

quired during axon development. In cultures, hippocampal and
neocortical neurons follow a stereotypic pattern of growth (Craig
and Banker, 1994; de Lima et al., 1997). When dissociated and
cultured, neurons form extensive filopodial and lamellipodial protrusions at the periphery (Stage 1) followed by extension of several
neurites (Stage 2). Subsequently one of these neurites elongates rapidly in an asymmetric manner to become the axon (Stage 3) followed
by dendritic specialization and growth (Stage 4) (Craig and Banker,
1994; de Lima et al., 1997). Hippocampal neurons cultured from
neonatal Srf-NestinCKO mice and control littermates were fixed
and stained for Tuj1 and MAP2 at the indicated time points and
axonal length (Tuj1 ⫹/MAP2 ⫺ process) was determined at each
time point (Fig. 5A). We found that neurons cultured from both
control and knock-out mice extended a single Tuj1 ⫹/MAP2 ⫺ process, which alone was positive for the axonal marker, Tau (data not
shown). In contrast, neurons from Srf-NestinCKO mice displayed
no or very few processes, which exhibited almost no growth in the
first 2 d (Fig. 5A,B). Subsequently, the average length of the axon in

SRF-deficient neurons increased slightly but still was significantly
lower than that of control neurons (Fig. 5A,B). At 5 d, SrfNestinCKO neurons exhibited significantly attenuated axon growth
along with an enlarged growth cone compared with Srf-f/f neurons
(Fig. 5A,B).
Analysis of axonal growth strongly suggested that the earliest
deficits exhibited by Srf-NestinCKO neurons are in Stage 1
growth. During Stage 1, cell symmetry is breached by filopodial
protrusions from cell soma, which is a necessary first step in the
generation of neurites (Craig and Banker, 1994; Dent et al., 2007).
To study Stage 1 growth in detail, hippocampal neurons from
Srf-NestinCKO and control littermates were fixed and stained
with phalloidin to visualize F-actin-rich filopodial protrusions at
12, 24, and 48 h after plating. We found that SRF-deficient neurons had very few or no filopodia at 12 and 24 h compared with
numerous filopodial protrusions exhibited by control neurons
(Fig. 5C,D; and data not shown). At 48 h, control neurons had
extended neurites with many filopodia at the tips. In contrast, the
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SRF-deficient neurons exhibited few or no distinguishable neurites or filopodia (Fig. 5A–D). SRF-deficient neurons also exhibited an enlarged growth cone as previously reported (Knöll et al.,
2006) and an enlarged cell soma. It has been reported that SRFdeficient neurons lack filopodia in growth cones of extending
axons (Stern et al., 2009). Because filopodia formation is a critical
step in neuronal growth, it is reasonable to speculate that the
severe Stage 1 growth deficits observed in Srf-NestinCKO neurons are likely the result of inability of mutant neurons to form or
stabilize filopodia. Together, these findings demonstrate that
SRF-dependent transcription plays a critical role in filopodia formation during early stages of axon growth.
Although SRF-deficient neurons exhibited highly attenuated
axonal growth, these neurons extended a single Tau-positive
axon indicating that cell polarity is not affected. To further confirm this, we immunostained hippocampal neurons from SrfNestinCKO mice and control littermates with a pan sodium
channel antibody (Pan-NaV) directed against the ␣ subU (intracellular III–IV loop) of all vertebrate channels. This Pan-NaV
antibody labels only the proximal part of the axon (Garrido et al.,
2003; Kress et al., 2010). We found that SRF-deficient neurons
extended a single Pan-NaV-positive neurite suggesting that neuronal polarity is not impaired in the absence of SRF (Fig. 5E).
Actin-binding protein, vinculin, can rescue growth defects of
SRF-deficient neurons
We next sought to identify the downstream target genes of SRF
that are important for axon growth. We performed a microarray
analysis to identify genes differentially expressed in the forebrain
of neonatal Srf-NestinCKO mutant mice and control littermates
(Fig. 6A). Because SRF-deficient neurons exhibited deficits in
filopodia formation, we reasoned that proteins that bind actin
and stabilize the actin cytoskeleton might be good candidates to
rescue axon growth. We therefore considered only those downregulated genes that are either part of, or interact with, the cytoskeleton and validated their expression using qRT-PCR (Fig. 6B).
We next asked which of these genes could rescue axonal growth in
SRF-deficient neurons. Expression of cortexin, nexillin, and
Rusc1 did not promote axonal growth in Srf-NestinCKO neurons
(data not shown). However, expression of VCL and microtubuleassociated protein 1B (MAP1B) was able to promote axon outgrowth in SRF-deficient neurons to varying extents. VCL is a
previously identified SRF target gene, and earlier studies using
chromatin immunoprecipitation and gene expression assays
have shown that Vcl is a direct target of SRF and MKL1
(Moiseyeva et al., 1993; Schratt et al., 2002; Miralles et al., 2003;
Cooper et al., 2007). VCL is an actin-binding protein and a component of cell–matrix junctions. In cultured CNS neurons, VCL
is localized in cell soma, at the ends of neurites and along with
focal adhesion kinase (Stevens et al., 1996; Contestabile et al.,
2003). Studies from cultured cells have shown that VCL functions
as a bridge between actin cytoskeleton and extracellular matrix
(Ziegler et al., 2006; Humphries et al., 2007). Despite these findings, the functions of VCL in the nervous system remain poorly
understood because of early embryonic lethality of Vcl-null mice
due to cardiac and neural tube defects (Xu et al., 1998). MAP1B is
a member of a large class of microtubule-associated proteins that
function in stabilizing the microtubule (Dehmelt and Halpain,
2004). It is important for axon growth, and its function is regulated by phosphorylation by GSK-3␤ (Dehmelt and Halpain,
2004; Gonzalez-Billault et al., 2004).
Expression of both Vcl and Map1b was severely attenuated in
the brains of Srf-NestinCKO mice (Figs. 6, 7A, and 8A). We

Figure 6. Putative SRF target genes identified from forebrain. A, Table represents Srf target
genes identified from forebrain of neonatal Srf-f/f and Srf-NestinCKO mice. The genes in bold
were further analyzed for their ability to rescue axonal growth deficits of Srf-NestinCKO mutant
neurons. B, mRNA expression of Srf target genes in A. Relative mRNA expression levels were
assessed by real-time qRT-PCR. The expression level in control sample was set to 1 (n ⫽ 3
experiments).

found that expression of Map1b partially rescued axonal growth
but failed to rescue the enlarged growth cone and abnormal cell
soma phenotypes observed in SRF-deficient neurons when cells
were grown on poly-D-lysine and laminin (Fig. 7 B, C). In contrast, Vcl expression was able to rescue axonal growth as well as
enlarged growth cone and cell soma phenotypes exhibited by
Srf-NestinCKO neurons when neurons were grown on poly-Dlysine and laminin (Fig. 8 B, C). Because VCL is a critical player in
coupling integrin signaling to the dynamic actin cytoskeleton, we
tested the ability of VCL to rescue axonal growth deficits of SRFdeficient neurons grown in the absence of laminin. We found
that Vcl expression only partially rescued axonal length of SRFdeficient neurons grown on poly-D-lysine alone in the absence of
laminin (Fig. 8 D, E). This suggested that efficient rescue of
growth deficits exhibited by SRF-deficient neurons by VCL likely
involves laminin and integrin signaling. Expression of VCL in
wild-type neurons did not have any additional growthpromoting effects (Fig. 8C,E). Together, these data suggest that
both VCL and MAP1B are capable of rescuing axon growth in
SRF-deficient neurons, but VCL is more efficient and VCL alone
can rescue the enlarged growth cone and cell soma morphologies.
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SRF-dependent axon growth. SRF is an
unprimed transcriptional substrate of
GSK-3, and GSK-3 inhibition results in
reduced SRF phosphorylation and SRF
activity, which attenuates axon growth.
Phosphorylation of SRF on serine 224 is
necessary for SRF to interact with its cofactors MKL1 and MKL2. Moreover, SRF
is sufficient to promote axonal growth
in the absence of GSK-3 signaling in
cultured hippocampal neurons. Furthermore, SRF regulates axonal growth through
regulation of VCL and MAP1B expression. Finally, knockdown of VCL attenuates axonal growth, and VCL can promote
axonal growth in the absence of SRF and
GSK-3 signaling. Together, our findings
suggest that SRF promotes axon growth
by likely activating gene expression downstream of GSK-3 signaling in hippocampal neurons.
Given the importance of SRF for neural development, activity-dependent gene
expression, and synaptic plasticity, surprisingly little is known about the posttranslational modifications that activate
SRF downstream of diverse cellular sigFigure 7. MAP1B expression is attenuated in SRF-deficient neurons. A, Lack of expression of MAP1B in SRF-deficient neurons. nals. Previous studies have shown that
SemiqRT-PCR of total RNA isolated from brains of Srf-NestinCKO mice and Srf-f/f control littermates (n ⫽ 3). RPS29 expression SRF is phosphorylated on several serine
served as the control. B, MAP1B expression partially promotes axon growth in SRF-null neurons. Hippocampal neurons from and threonine residues, but the imporneonatal Srf-NestinCKO mice were transfected with either control myc vector or myc-tagged MAP1B along with farnesylated GFP tance of this phosphorylation for SRF
(F-GFP)andgrownfor4donpoly-D-lysineandlaminin.MAP1BwasabletopartiallyincreaseaxonallengthinSRF-deficientcells.However, transcriptional activity remains unclear
MAP1B was not efficient in rescuing the enlarged growth cone (arrows) and abnormal cell soma (arrowheads) morphologies observed in (Misra et al., 1991; Rivera et al., 1993; Iyer
SRF-deficient neurons. Expression of MAP1B did not increase axonal growth in WT neurons. Scale bar, 50 mm. C, Quantitation of axon et al., 2006). In this study, we have identilength and growth cone area from B. ***p ⬍ 0.001 (one-way ANOVA and Tukey post-test analysis). n.s., Not significant.
fied a novel phosphorylation mechanism
by which SRF is activated in neurons and
Phosphorylation of SRF by GSK-3 promotes SRF-MKL1
how
this
contributes
to
SRF-dependent axon growth (Fig. 10).
binding, and SRF and MKL1 regulate Vcl expression (Schratt et
SRF is directly phosphorylated by GSK-3 on ser224 that lies outal., 2002; Miralles et al., 2003). Based on these observations, we
side the MADS-domain required for DNA binding and SRF hoasked whether VCL can also promote axon growth when GSK-3
modimerization (Pellegrini et al., 1995). Furthermore, global
is inhibited. We first assessed the status of Vcl expression under
inhibition of GSK-3 activity in cultured neurons attenuated SRF
conditions of GSK-3 inhibition and subsequent rescue by SRFphosphorylation and SRF transcriptional activity (Figs. 1 and 9).
VP16 (Fig. 9A). Hippocampal neurons treated with 6-BIO exhibHowever, currently it remains unknown whether the decrease in
ited significant reduction in Vcl mRNA expression as determined
SRF phosphorylation is the result of GSK-3␤ inhibition in the
by qRT-PCR, and expression of SRF-VP16 in the presence of
nucleus or axons and whether nucleus-specific GSK-3 inhibition
6-BIO resulted in increased Vcl mRNA (Fig. 9A). We next exalone can block axon growth. A recent study revealed a novel
pressed VCL in wild-type hippocampal neurons grown in the
mechanism by which cytoplasmic SRF promoted axon regenerapresence of 6-BIO and found that VCL expression significantly
tion after peripheral nerve injury in a transcription-independent
increased axon length (Fig. 9 B, C). Last, we asked whether VCL is
manner through interactions with cofilin (Stern et al., 2013). It is
necessary for axon growth. Using shRNA specific for mouse Vcl,
possible that pSer224-SRF might have a similar cytoplasmic role
we found that Vcl knockdown resulted in attenuated axonal
during axon growth. However, this is unlikely because the
growth similar to that observed in SRF-deficient neurons (Fig.
SRF S224A point mutant acted in a dominant-negative manner
9 D, E; and data not shown). Coexpression of a chicken homolog
and attenuated both transcription and axon growth. Future exof Vcl, which is functionally similar to mouse Vcl, rescued axonal
periments will address the effect of nucleus- and axon-specific
growth (Fig. 9 D, E) (Grashoff et al., 2010). The chicken Vcl is
inhibition of GSK-3 on SRF phosphorylation and axon growth.
resistant to mouse shVcl, suggesting that axonal growth deficits
Previous studies have shown that GSK-3␤ can shuttle between
caused by shVcl are not the result of off-target effects. Together,
cytoplasm
and nucleus and that GSK-3␤ is present in the nucleus
these observations demonstrate that SRF promotes axon outwhere it interacts with transcription factors (Bijur and Jope, 2003;
growth downstream of GSK-3 partly through regulation of
Caspi et al., 2008; Bechard and Dalton, 2009). In the context of
MAP1B and VCL expression.
GSK-3/SRF interaction, it remains unclear whether SRF is conDiscussion
stitutively phosphorylated by GSK-3 in the nucleus or whether
In this study, we report a novel phosphorylation of SRF, mediated
their interaction is triggered by growth-promoting signals and/or
by GSK-3, that is required for SRF transcriptional activity and for
actin-cytoskeletal changes. Future studies will address whether
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Figure 8. Vinculin is sufficient to promote axonal growth in SRF-deficient neurons. A, Western blot of total brain lysate showing reduced Vcl expression in Srf-NestinCKO mice compared with
control littermates. B, P0.5 hippocampal neurons from Srf-NestinCKO and Srf-f/f mice were cotransfected with empty vector (pMyc) or pMyc-VCL and cultured for 4 DIV on poly-D-lysine and laminin.
Cells were fixed and immunostained for Tuj1 (red) and Myc (green). Expression of Vcl but not empty vector was able to promote axon growth. Scale bar, 25 m. C, Quantitation of B. Error bars indicate
SEM. ***p ⬍ 0.001 (one-way ANOVA, Tukey post-test analysis). n.s., Not significant. D, Vinculin only partially rescues axonal growth in SRF-deficient neurons in the absence of laminin. P0.5
hippocampal neurons from Srf-NestinCKO and Srf-f/f mice were cotransfected with empty vector (pMyc) or pMyc-VCL along with farnesylated-GFP (F-GFP) and cultured for 4 DIV on poly-D-lysine
alone without laminin. Cells were fixed and immunostained for GFP (green) to visualize neuronal morphology and Myc (red) for transfected cells. Expression of VCL, but not empty vector, could
partially rescue axonal growth in the absence of laminin, suggesting a role for laminin–integrin signaling downstream of VCL in promoting axon growth. Scale bar, 25 m. E, Quantitation of axon
length in D. ***p ⬍ 0.001 (one-way ANOVA, Tukey post-test analysis).
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Figure 9. Vinculin can partially rescue axonal growth in the absence of GSK-3 signaling. A, Vcl mRNA expression is attenuated in neurons when GSK-3 is inhibited. Vcl mRNA expression was
assessed by real-time qRT-PCR from total RNA isolated from hippocampal neurons grown in the presence of DMSO (con), 500 nM 6-BIO or 6-BIO⫹SRF-VP16 at 3 DIV. Vcl mRNA levels decreased in
the presence 6-BIO and expression of SRF-VP16 rescued Vcl levels. ***p ⬍ 0.001 (one-way ANOVA, Tukey post-test analysis). n.s., Not significant. B, VCL expression was also able to promote axonal
growth when GSK-3 is blocked by 6-BIO. Wild-type hippocampal neurons were transfected with either empty Myc vector or Myc-VCL and cultured in the presence of DMSO (vehicle) or 500 nM 6-BIO
for 4 DIV on poly-D-lysine and laminin. Cells were fixed and immunostained for Myc (green) and Tuj1 (red). VCL expression alone promoted axonal growth (arrow). Scale bar, 25 m. C, Quantitation
of B. Error bars indicate SEM. **p ⫽ 0.005 (6-BIO⫹Myc vs 6-BIO⫹Myc-VCL) (two-tailed t test analysis). ***p ⫽ 0.0002 (6-BIO⫹Myc vs 6-BIO⫹Myc-VCL) (two-tailed t test analysis). D, shRNA
knockdown of VCL expression in hippocampal neurons attenuates axonal growth. Wild-type hippocampal neurons were transfected with shRNA targeting mouse Vcl (Vcl-shRNA-CMV-mCherry) or
a control shRNA (shRNA-CMV-mCherry) along with YFP and grown for 4 d. Cells were fixed and stained for mCherry encoded from within the shRNA vector and YFP. For rescue experiment, neurons
were transfected with Vcl-shRNA along with the chicken homolog, venus-chicken Vcl (Ch-Vcl). Ch-Vcl is resistant to mouse Vcl-shRNA, and its expression rescued axonal growth (arrow). Scale bar,
25 m. E, Quantitation of D. Error bars indicate SEM. **p ⬍ 0.01 (one-way ANOVA, Tukey post-test analysis). ***p ⬍ 0.001 (one-way ANOVA, Tukey post-test analysis).

extrinsic factors, such as neurotrophins and actin cytoskeletal
changes, result in SRF ser224 phosphorylation. These studies will
provide additional insights into how extracellular signals are conveyed to the nucleus for efficient axonal growth.
During development, we observed that ser224 phosphorylation on SRF increased between E15.5 and E18.5 and decreased

subsequently. In contrast, at E15.5, we found relatively higher
GSK-3␤-Ser9 phosphorylation, a measure of its inactivation.
Thus, it seems to appear that SRF-Ser224 phosphorylation does
not closely correlate temporally with GSK-3␤ activity in the
brain. A parsimonious explanation for this is that we measured
total GSK-3␤ activity in whole-brain lysates, and this might not
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accurately reflect the activity of nuclear
GSK-3␤. However, a previous study had
shown that GSK-3␤ activity increases
during brain development when assessed
for GSK-3␤ targets, such as c-Myc and
␤-catenin (Kim et al., 2009), and these
findings appear to be consistent with our observations for SRF ser224 phosphorylation.
The ser224 phosphorylation is specifically required for SRF to form a functional
transcriptional complex with the cofactors MKL1 and MKL2 and not with ELK1.
Among these two groups of cofactors, the
MKLs alone have been shown to regulate
axonal and dendritic growth in hippocampal, neocortical, and embryonic
DRG neurons (Shiota et al., 2006; Wickramasinghe et al., 2008; Mokalled et al.,
2010; O’Sullivan et al., 2010). The role for
TCF-family members in neuronal development remains unclear. We found that,
unlike dominant-negative MKL2, expression of a dominant-negative ELK1-En,
which inhibits all TCF-family members,
in cultured hippocampal neurons did not Figure 10. Summary model. Model of GSK-3-SRF signaling pathway in regulation of axon growth. Phosphorylation by GSK-3 on
affect axon growth (Fig. 3G,H ). There- serine 224 results in the activation of SRF and subsequent recruitment of MKL-family cofactors. The SRF-MKL transcriptional
fore, it appears that TCF-target genes are complex activates genes, such as VCL and MAP1B. MAP1B regulates microtubule dynamics, whereas VCL tethers F-actin to focal
unlikely to regulate axon growth in hip- adhesion junctions to promote neurite growth downstream of the GSK-3-SRF pathway. Absence of SRF or GSK-3 activity results in
pocampal neurons. Based on these obser- inhibition or attenuation of neurite growth.
vations, we speculate that SRF S224A acts as
a dominant-negative mutant by forming heterodimers with enhave shown that ␤-actin is a transcriptional target of SRF, suggesting that neurite outgrowth deficits exhibited by SRF-deficient
dogenous wild-type SRF, thereby preventing the formation of a
neurons are likely the result of reduced actin levels (Ramanan et
functional SRF-MKL complex. Currently, it is unclear whether
al., 2005; Knöll et al., 2006). However, expression of full-length
the ser224 phosphorylation is also required for other functions of
actin or various mutant forms of actin did not rescue growth
SRF, including activity-dependent immediate early gene expresdeficits in SRF-deficient hippocampal neurons (Knöll et al., 2006;
sion and synaptic plasticity (Ramanan et al., 2005).
Previous studies have shown that pharmacological inhibition
Stern et al., 2009). Our findings suggest that it is likely that the
of the MEK pathway or expression of dominant-negative
axonal defects observed in SRF-deficient neurons are not the
ELK1-En did not affect Vcl expression (Gineitis and Treisman,
result of reduced actin expression, but rather the absence of pro2001; Vickers et al., 2004). Instead, expression of DN-MKL1,
teins, such as VCL, which are required for mechanical coupling of
which blocks both MKL1 and MKL2 or inhibition of actin pothe actin cytoskeleton to focal adhesion sites. Therefore, restoring
lymerization by latrunculin-B blocks Vcl expression (Gineitis and
VCL expression in SRF-deficient neurons may suffice to assemble
Treisman, 2001; Cen et al., 2003). Together, these findings imply
the actin cytoskeleton and provide the necessary driving force to
that Vcl expression is independent of Elk1/TCF-family members
promote axonal growth.
and ERK/MEK pathway activation. Consistent with these findWe observed that, whereas VCL expression could rescue axings, we found that ELK1-En expression did not inhibit axon
onal growth in SRF-deficient neurons, VCL ability to rescue axoutgrowth, whereas DN-MKL2 expression profoundly inhibits
onal growth in GSK-3-inhibited neurons was only partial,
growth likely by inhibiting genes, including Vcl.
suggesting the involvement of other GSK-3 targets and/or pathInterestingly, hippocampal neurons lacking SRF or inhibited
ways. It has been shown that GSK-3 regulates axon growth by
for GSK-3 activities exhibit similar growth phenotypes in culture.
regulating the activity of several microtubule-associated proteins,
Both these groups of neurons exhibit a delay in Stage 1 growth
including MAP1B, CRMPs, and APC (Zhou et al., 2004; Goold
and Gordon-Weeks, 2005; Kim et al., 2006; Alabed et al., 2010).
observed in the first 12–24 h (Fig. 5; and data not shown). However, SRF-deficient neurons were able to extend a single but sigMAP1B is activated by GSK-3 phosphorylation and contributes
nificantly shorter axon at 5 DIV. In contrast, consistent with
to microtubule dynamics (Goold and Gordon-Weeks, 2005).
previous studies, complete inhibition of GSK-3 exerts a more
Therefore, in the absence of these critical GSK-3 targets, VCL
profound effect and neurons fail to extend an axon (Kim et al.,
could promote axon growth in GSK-3 inhibited neurons only to
2006; Garrido et al., 2007).
a limited extent.
Our work identifies VCL as a critical mediator of axon growth
GSK-3 inhibitory drugs are commonly used to treat neurodownstream of GSK-3/SRF signaling. VCL is a major component
psychiatric and neurological disorders, including bipolar disorof cell-matrix adhesions and acts as a critical link between focal
der, Parkinson’s disease, and Alzheimer’s disease (Bhat et al.,
2004; Cohen and Goedert, 2004). SRF has been shown to play a
adhesions and the actin cytoskeleton through direct interaction
critical role in immediate early gene expression, synaptic plasticwith several binding partners, including talin, paxillin, and actin
ity, and learning and memory, whereas SRF cofactors MAL/
(Ziegler et al., 2006; Humphries et al., 2007). Previous findings
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MKLs are important for cerebellar long-term depression (Ramanan
et al., 2005; Etkin et al., 2006; Smith-Hicks et al., 2010). It is likely
that targeting GSK-3 in the treatment of the above disorders
might also affect SRF-dependent neuronal development and
plasticity. Future studies will probe the effect of anti-GSK-3 therapeutics on SRF transcriptional activity and its critical functions
in the nervous system.
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